Johnson & Johnson is a global American pharmaceutical and consumer goods company with headquarters in New Brunswick, New Jersey. The company is listed in the Dow Jones Industrial Average.
According to Johnson & Johnson's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.2767. At the end of 2022 the company had a P/E ratio of 25.9.
Year | P/E ratio | Change |
---|---|---|
2022 | 25.9 | 19.85% |
2021 | 21.6 | -23.35% |
2020 | 28.2 | 33.07% |
2019 | 21.2 | -6.74% |
2018 | 22.7 | -92.46% |
2017 | 301 | 1460.23% |
2016 | 19.3 | 4.46% |
2015 | 18.5 | 2.49% |
2014 | 18.0 | -3.32% |
2013 | 18.6 | 4.62% |
2012 | 17.8 | -3.85% |
2011 | 18.5 | 45.08% |
2010 | 12.8 | -12.21% |
2009 | 14.5 | 12.32% |
2008 | 13.0 | -28.94% |
2007 | 18.2 | 3.79% |
2006 | 17.6 | -1.25% |
2005 | 17.8 | -22.81% |
2004 | 23.0 | 8.57% |
2003 | 21.2 | -13.1% |
2002 | 24.4 | -23.17% |
2001 | 31.8 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.